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Nanoparticles obtained by Confined Impinging Jet Mixer: Poly(lactide-co-
glycolide) vs. Poly-ε-caprolactone 
 
Abstract 
This paper is focused on the production and characterization of polymeric nanoparticles 
obtained by nanoprecipitation. The method consisted of using a Confined Impinging Jet 
Mixer (CIJM), circumventing high-energy equipment. Differences between the use of poly-ε-
caprolactone (PCL) and poly(lactide-co-glycolide) (PLGA) as concerns particle mean size, 
zeta potential, and broad spectrum antibiotic florfenicol  entrapment were investigated. Other 
analyzed variables were polymer concentration, solvent and anti-solvent flow rates, and 
antibiotic initial concentration. To our knowledge, no data were found related to PLGA and 
PCL nanoparticles comparison using CIJM Also, florfenicol encapsulation within PCL or 
PLGA nanoparticles by nanoprecipitation has not been reported yet. The complexity of the 
nanoprecipitation phenomena has been confirmed, with many relevant variables involved in 
particles formation. PLGA resulted in smaller and more stable nanoparticles with higher 
entrapping of florfenicol than PCL. 
  
Keywords: Nanoprecipitation, Nanotechnology, Biodegradable polymers, PLGA, PCL, 
Polymeric drug carriers. 
 
 
1. Introduction 
Nanoparticles are colloidal systems with sub-micron particles size where the drug can be 
encapsulated, adsorbed or dispersed. As advantages with respect to other systems, they can be 
injected directly in the blood stream and their nanoparticle size (for intravenous 
administration necessarily below 250 nm) reduces the reticulo-endothelial system’s 
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interactions, enhancing the circulation time [1]. This allows an increased accumulation of the 
particles (and of the entrapped drug) in tissues with increased vascular permeability and 
reduced lymphatic drainage such as tumors and inflamed tissues. This phenomenon, named as 
enhanced permeability and retention effect, is a way of passive targeting of nanoparticles [2-
3]. 
In comparison with microparticles, nanoparticles can be obtained with almost the same 
techniques varying, among many others variables, the energy applied to emulsion formation, 
viscosity of continuous phase, concentration of surfactants, phase ratios. In particular, 
nanoparticles can be prepared by solvent-displacement, a technique also known as 
nanoprecipitation. By this method a hydrophobic polymer and the drug are dissolved in an 
organic water-miscible solvent, which is then mixed with an aqueous medium (with or 
without surfactants or additives). The solvent quickly diffuses in the water phase leading to 
polymer precipitation and nanoparticle formation. The diffusivity rate of the solvent into the 
non-solvent phase, which depends on the characteristics of the system and is related to the 
dielectric constant of the solvent, plays an important role and finally affects the size of the 
produced nanoparticles [4-6]. This method is low-energy demanding, easy and fast [7]. It is 
important to evidence that even if no surfactants are necessary to obtain nanoparticles by 
nanoprecipitation [8] they can be useful in some cases. 
A special case of solvent-displacement is achieved with Confined Impinging Jet Mixers 
(CIJM) in which mixing in the center of a cylindrical chamber is extremely rapid due to the 
two inlet opposite streams of organic/polymeric and aqueous phases [9-10]. The main 
advantage of this technology is the possibility to control both the size distribution and the 
surface properties of nanoparticles by varying formulation and operating conditions, e.g. 
polymer type and concentration, reactor geometry, solvent type, stream flow rates, quench 
volumetric ratio, water-to-organic flow rate ratio [6, 11-13]. Turbulent mixing is important in 
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this type of devices and allows obtaining smaller particle sizes in comparison to preparation 
methods where the solution is added drop by drop to the antisolvent. In this latter case, the 
controlling mixing mechanism can be different: the viscosity of the polymer solution may be 
relevant because the regime is mainly laminar and particle formation is governed by 
Marangoni effect, due to interfacial turbulence [5, 14]. 
The previously cited articles studied the effect of the relevant variables using 
poly(methoxypolyethylene glycol cyanoacrylate-co-hexadecyl cyanoacrylate) 
(poly(MePEGCA-co-HDCA)), PEG-b-poly(lactide) and poly-ε-caprolactone (PCL) for the 
entrapment of different hydrophobic drugs but information related to poly(lactide-co-
glycolide) (PLGA) and PCL nanoparticles comparison using CIJM has not been previously 
reported. 
PCL and PLGA are preferably used as polymeric matrix in pharmaceutical formulations 
because of their approval by the FDA. PCL and PLGA (Fig. 1) are synthetic aliphatic 
polyesters commonly used in the design of controlled release formulations because of their 
biodegradability (by bulk hydrolysis of the ester bonds) and biocompatibility properties [15]. 
Advantages related to PLGA formulations are based on their versatility: molecular weight, 
ratio of polylactide to polyglycolide, end-group of polymeric chains can be modified and 
adjusted to meet required release patterns of a dosage form [16]. The advantages of PCL in 
comparison with PLGA are its slower degradation, its low cost and its ability to form blends 
with other polymers [1, 17].  
Florfenicol (2,2-dichloro-N-[(1R,2S)-3-fluoro-1-hydroxy-1-(4-
methanesulfonylphenyl)propan-2-yl]acetamide) (Fig. 1) is a broad-spectrum antibiotic, 
demonstrating to be active (bacteriostatic) against many gram-negative and gram-positive 
organisms. Florfenicol molecule has a fluorine atom in its structure making it more resistant 
to deactivation by bacteria than chloramphenicol. Florfenicol commercial formulations are 
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indicated in the treatment of respiratory infections and pododermatitis in cattle [18]. Song et 
al. [19] obtained silica nanoparticles with adsorbed florfenicol, Kou et al. [20] studied its 
adsorption on molecularly imprinted nanospheres obtained by premix membrane 
emulsification method, Pinto et al. [21] prepared florfenicol-PLGA nanoparticles using an 
emulsion/diffusion/evaporation method, and Wang et al. [22] prepared florfenicol-loaded 
solid lipid nanoparticles by hot homogenization and ultrasonic technique. To our knowledge, 
florfenicol encapsulation within PCL or PLGA nanoparticles using nanoprecipitation in CIJM 
has not been reported yet. The feature of being slightly soluble (and not insoluble) in water 
makes its loading into hydrophobic polymeric matrices challenging.  
In the present contribution, authors studied the influence of the polymer (PCL or PLGA) 
characteristics over particles size and florfenicol entrapment using the solvent displacement 
technique in a CIJM which, as discussed, is a technique that allows reproducible and 
controlled production of nanocarriers for controlled release.  
 
2. Materials and Methods 
2.1 Materials 
Commercially available uncapped low molecular weight 50:50 PLGA Resomer® RG502H 
(Mw 8650 Da, Boehringer Ingelheim Pharma KG, Germany), PCL (Mw 14000 Da, Sigma-
Aldrich, Germany), florfenicol (99.2%, Chemo Romikin, Argentina), acetone (Sigma-
Aldrich, Germany) were used for nanoparticles preparation. Ultrapure water was used as non-
solvent phase (Milli-Q RG, Millipore System, Germany). 
2.2 Nanoparticles Preparation 
The nanoprecipitation method was implemented, using a CIJM for the precipitation of the 
polymer. Acetone has been selected as polymer solvent for its high diffusivity in water, which 
allows to obtain smaller particles than other solvents (like dimethylformamide or 
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tetrahydrofuran) without the undesired upsizing phenomenon at high Reynolds number [6]. 
The used CIJM consisted of a T-type mixer with an internal mixing chamber, two opposite 
inlet tubes, and one outlet tube (Fig. 2). The CIJM was used as a passive mixer where the 
polymer-containing acetone solution (eventually containing also the drug) and water streams 
were fed into the chamber by a syringe pump (KDS200; KD Scientific, USA) and mixed 
under turbulent flow conditions thanks to the kinetics energy of the impinging jets [9, 23]. 
Equal water and solvent flow rates were considered in this work. In order to kinetically freeze 
the produced nanoparticles and stabilize the particle suspension, the outlet stream was 
collected into water and kept gently stirred. A quench ratio of 1:1 (ratio between quantity of 
water used in CIJM and water in the collecting bath) was used [13]. Acetone was completely 
evaporated from suspension in a rotary evaporator (Stuart Rotary Evaporators, Bibby 
Scientific Ltd., UK) for 30 min.  
In a first instance, three different flow rates and three initial polymer concentrations in 
acetone were evaluated for blank nanoparticles preparation using PCL and PLGA polymers. 
After the characterization of these nanoparticles, variable drug initial concentrations were 
included in the polymer containing phase (at fixed polymer concentration of 6 mg/mL) and 
different flow rates were investigated to evaluate the effect over particle mean size and 
surface zeta potential. The encapsulation of florfenicol was evaluated in nanoparticles 
obtained under the following conditions: polymer concentration 6 mg/mL and flow rate 80 
mL/min. In Table 1 operating parameters are summarized for all the prepared particles. After 
acetone evaporation, nanoparticles suspensions were stored at 4ºC for further analysis. Assays 
were conducted in triplicate to study the reproducibility of the methodology. 
2.3 Nanoparticles Characterization 
2.3.1 Mean Size and Zeta Potential 
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First, each suspension was diluted properly with ultrapure water. Then, the size distribution 
was analyzed by dynamic light scattering (Zetasizer Nanoseries ZS, Malvern Instrument). The 
mean size value from the intensity distribution (called the Z average) and the polydispersity 
index (PDI), to describe the size distribution width, were considered. Electrophoretic 
measurements made on the same equipment were done to calculate the zeta potential of the 
nanoparticles. Data were analyzed using statistical tools (ANOVA and Fisher LSD tests). The 
differences between experiments were considered significant when p < 0.05. 
2.3.2 Drug Incorporation 
The drug encapsulation efficiency and the drug loading were estimated with an indirect 
method, consisting in the centrifugation of a fixed volume of suspension, containing a known 
mass of nanoparticles (Mnp) (45,000 rpm for 90 min; Ultracentrifuge L5-50B, TY65 rotor 
type, Beckmann) and determining the unloaded mass of drug (Muld) in the supernatant. 
Concentration of florfenicol was measured spectrophotometrically at 223 nm (Beckman Du-
700), using a previously obtained calibration curve in water (R2 = 0.999). 
The loaded mass of antibiotic could be calculated as difference between the initial mass of 
florfenicol used during nanoparticles preparation (Mi) and Muld. As a result, the quantity of 
entrapped drug (drug loading, En) was estimated based on Eq. (1): 
100(Mi Muld)%En
Mnp
−
=  (1) 
in which En is grams of entrapped florfenicol in 100 g of nanoparticles (% w/w). Eq. (2) was 
used to calculate the encapsulation efficiency (Ee): 
( )% 100Mi MuldEe
Mi
−
=  (2) 
 
3. Results and Discussion 
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Mean size of nanoparticles obtained at different flow rates and at three polymer 
concentrations of PCL and PLGA is shown in Figure 3a. Results are presented as mean values 
and standard deviations of three independent assays. The 94% of variations between 
repetitions of the same assay resulted in deviations lower than 9.1% on the mean particle size, 
demonstrating high reproducibility of nanoparticles preparation method.  
For PLGA, PCL, and poly(MePEGCA-co-HDCA) polymers, literature reported the decrease 
of nanoparticles mean size with the increment of flow rates for nanoprecipitation processes in 
intensive mixers [13, 23] and fluidic devices [24]. In fact, it is generally accepted that an 
increase in the flow rates of the two opposite streams will produce a higher number of smaller 
particles, because the improved mixing performance favors the formation of higher 
supersaturation levels and thus higher nucleation rates. Equivalently, if formation by self–
assembly is assumed, the particle size is proportional to the ratio of the mixing and 
coalescence, but the process can still be approximated by the expression used for 
homogeneous nucleation. The size-flow rate-concentration relationships can be described by 
the following power law: 
polp jd Av c
β α=  (3) 
where dp is the mean nanoparticle size, A is a coefficient that depends on polymer and also on 
the geometry of the mixer, vj is the inlet fluid velocity, both α and β are parameters from 
power law equation (where α=0.29 and β=–0.18 for both polymers [13]), and cpol is the initial 
polymer concentration. From present data, the dependence of particle size on vj (variable 
which is proportional to the volumetric feed flow rate) does not appear to be very strong. 
Anyway, it must be considered that the particle volume is proportional to the cube of the 
diameter, and considering this variable, its dependence on inlet velocity is more significant. 
The effect is generally evident particularly at flow rates lower than the investigated range, 
where the flow is not completely turbulent. In addition, when the mixing time becomes 
  
9 
 
comparable with the characteristic particle formation time, the increase of the mixing 
efficiency, obtained increasing the feed rate and thus the turbulence intensity, increases 
productivity but has no beneficial effect on the particle size. The break point occurs in this 
case at flow rate in the range 50-80 mL/min. On the contrary, the increase of turbulence level 
is responsible for higher pressure drops and can favor aggregation phenomena; it must be 
remembered anyway that for particles lower than micron size Brownian (perikinetic) 
aggregation is more important than orthokinetic one [25]. 
The curves shown in Figure 3a are those predicted with the power law relationship given in 
Eq. (3). The obtained results are in agreement (considering experimental uncertainty) with 
previous results obtained with the same device for PCL, confirming the dependence of 
particle size on vj–0.18. Figure 3a also evidences a similar dependence for PLGA.  
The differences between the two polymers could be attributed to differences in the respective 
characteristic particle formation time. Literature results have shown that the particle size 
dependence on inlet fluid velocity can change in a very limited range for different polymers; 
the size of the particles that can be obtained, on the other hand, can be largely different, as in 
the present case, because it depends on polymer structure and also on molecular weight [26]. 
As a consequence, for a given initial polymer concentration, also the number of particles 
formed is very different, which  can be easily estimated considering that the precipitation is 
very fast and yield is generally close to unit [27]. In the investigated range PLGA 
nanoparticles have a diameter that is about one third of the PCL ones, but their number is 20-
40 times larger in the different operating conditions. 
The role of viscosity is generally marginal for solvent displacement in this turbulent regime, 
differently from what has been proposed using different techniques, like the emulsion 
polymerization, where the size of the formed droplets may be affected by the polymer 
solution viscosity [28-30].  
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The effect of polymer concentration on mean particle size is evidenced in Figure 3b. The 
increase observed for both PCL and PLGA is in agreement with previous findings for various 
polymers and can be described by the same power law type relationship (see Eq. (3)), 
indicating that, in this relatively low concentration range, particle formation can be interpreted 
by a nucleation-aggregation mechanism that is typical of high supersaturation conditions [26, 
31]. Exponent values reported in literature for different polymers vary in a wider range than 
for the flow rate dependence, but for PCL and PLGA the data obtained in this work suggest 
the same dependence (that is size proportional to cpol0.29).  
A similar trend for size increment as a function of polymer concentration was reported by 
Bilati et al. [5] and Sonam et al. [14] for PLGA nanoprecipitation by syringe method; this was 
attributed to an increment in viscosity of solvent-polymer solution and a change in solvent 
diffusivity parameter during nanoparticles preparation. As discussed before, in case of 
turbulent precipitation in CIJM, viscosity is not influent, at least for acetone and in this 
polymer concentration range.  
In the spontaneous process of solid particles formation, the final nanoparticle number and size 
is determined by rate of mixing, nucleation and self-assembling, growth and aggregation. The 
nucleation rate, as discussed, depends on polymer structure and solvent phase composition, 
and can be estimated for example by Molecular Dynamics [32-34]. 
A further difference in the behavior of PCL and PLGA can be evidenced looking closer at the 
relative size variation of the particles. In fact, if the size-flow rate-concentration relationships 
were perfectly described by the power laws previously proposed in Eq. (3) (and showed in 
Figure 3a and 3b), the relative size variation of the particles should be the same at any flow 
rate. Figure 4a shows the values of the relative size increments (that is the size variation with 
respect to the case with the lowest polymer concentration tested, 2.5 mg/mL, at the same flow 
rate). Even if the data must be analyzed with caution, because small differences may be 
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strongly affected by experimental uncertainty, the different trend is evident. The quantitative 
justification is difficult due to the complexity of the phenomena involved, but the increase 
observed at higher flow rate for PCL can be explained with size increase due to aggregation. 
PCL nanoparticles are less stable than PLGA nanoparticles (as shown by the comparison of 
the respective zeta potential values), and growth by particle aggregation may be more 
relevant.  
More difficult is the explanation of the PLGA behavior, which is probably related to the role 
of nucleation, which is more important for this polymer as demonstrated by the smaller 
average size and is influenced by polymer concentration in a strongly non-linear way. 
Estimating the number of particles formed, in fact, it can be noted that the smaller size 
increase for PLGA corresponds to a stronger increase in particle number. 
The variation of the polydispersity is shown in Figure 4b; the graph describes the dependence 
of the distribution width on the inlet polymer concentration. The efficacy of nanoparticle 
formulations is based on their nano-size and low polydispersity, ensuring injectability, 
reproducibility, appropriate circulating time in blood, and release performance. It is worth to 
note that, independently of the type and concentration of polymer and flow rates, all 
nanoparticles suspensions had a PDI lower than 0.20 and can be considered monodispersed 
distributions [35]. Besides the fact that PCL nanoparticles reach greater mean size values, 
their PDI was significantly lower than PLGA and below 0.10. This confirms the complexity 
of the nanoprecipitation phenomenon, where many variables (more than those analyzed in the 
present contribution) are involved during particles formation. Since acetone is miscible with 
water, there is no emulsification step and nanoparticles formation starts immediately [36]. 
Under the same operating conditions, differences in polymer solubility in both solvent and 
non-solvent would determine variations between PCL and PLGA precipitation conditions 
(supersaturation, self-assembling rate, Ostwald ripening) and final size distribution properties 
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of particles [24]. Moreover, Bilati et al. [5] found that a more hydrophobic polymer produced 
larger particles by nanoprecipitation using the syringe method. In the present contribution, 
this empirical rule seems confirmed as the more hydrophobic PCL (semi-crystalline polymer) 
compared with PLGA (amorphous polymer) [15, 17] forms bigger nanoparticles (about 300 
nm against 100 nm) (Fig.1 and 3a). 
Zeta potential values of all studied nanoparticles are presented in Figure 5a. All nanoparticles 
resulted negatively charged due to the presence of ionized carboxylate end-groups from PCL 
and PLGA polymeric chains on particle surface [7, 37]. The particle surface charge is a factor 
that determines the physical stability of nanoparticles. The higher is the absolute zeta potential 
value, the more stable is the nanoparticles suspension; in fact, when particles are largely and 
equally charged, the electrostatic repulsion forces between the particles are higher and 
agglomeration diminishes [38]. For both analyzed polymers the particle stability was higher 
for the larger particles, produced starting from higher initial polymer concentrations; no 
significant influence of flow rate was evidenced. 
Comparing the results obtained for the two different polymers, it can be noted that PLGA 
nanoparticles reach zeta potential values between –32 and –40 mV while PCL values were 
above –25 mV. In scientific and industrial fields, the common dividing line between unstable 
and stable suspensions is taken as +30 or –30 mV: therefore PLGA formulation can be 
considered as physically stable while PCL suspensions have a lower stability [39]. Despite 
this, all the PCL suspensions prepared from different initial concentration of polymer 
maintained the initial properties with respect to mean size after three months of storage at 4ºC 
(p > 0.05) (data not shown). In Figure 5b it can be seen a linear regression analysis between 
zeta potential and mean size values of all prepared nanoparticles. Especially in case of PCL, 
the inverse proportionality is clearly evident (R = 0.922), at least in the investigated range. It 
is well known that reducing the size distribution of dispersion, stability is increased because 
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sedimentation or cremation effects are reduced [30]. In this case, the effect is counteracted by 
zeta potential variation, because for smaller sizes the absolute zeta values decrease. 
Florfenicol was incorporated during nanoparticles preparation in the acetone phase at four 
concentrations levels between 0.5 and 5 mg/mL (see Table 1 for additional information on 
operating parameters). Mean size and zeta potential of nanoparticles prepared from 6 mg/mL 
PCL and PLGA solutions at three flow rates are shown in Table 2 and Table 3, respectively. 
In most cases, nanoparticles did not significantly change their size when the concentration of 
florfenicol increased. Similar results were reported by Corrigan and Li [40] after the 
entrapment of indomethacin and ketoprofen inside PLGA RG504 nanoparticles by single 
emulsion technique. It is important to mention that in literature generally the size increases 
with loading [26, 41]. 
To confirm the drug entrapment, En was evaluated for nanoparticles prepared at a flow rate of 
80 mL/min. Results for PCL and PLGA nanoparticles are shown in Table 4. Entrapped 
quantities of antibiotic increased when greater initial amounts of florfenicol were used during 
nanoparticles preparation. Similar results were reported by other authors for different solvent-
polymer-drug systems using the nanoprecipitation method [4, 8, 41-42]. Pinto et al. [21] also 
increased florfenicol encapsulation efficiencies into PLGA nanoparticles by 
emulsion/diffusion/evaporation method and varying the initial mass of drug. Taking into 
account the polymer type, PCL leads to nanoparticles with significant levels of loaded 
florfenicol only at antibiotic initial concentrations higher than 2 mg/mL. At initial florfenicol 
concentration of 0.5 and 1 mg/mL no drug entrapment could be detected. Despite this, a 
notable increment in En was achieved at 5 mg/mL florfenicol concentration with values 
around 10% w/w. For PLGA nanoparticles, the increment was more gradual, with En values 
varying from 0.76 to almost 13% w/w for the four initial antibiotic concentrations. It is worth 
to note that PLGA nanoparticles with a mean size around 95 nm entrapped almost four times 
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more florfenicol than PCL nanoparticles (260 nm) when initial 2 mg/mL of antibiotic was 
used (Tables 2-4). This different behavior could be related to physico-chemical differences 
between obtained polymeric matrixes and to different mechanisms of incorporation that can 
be connected to differences in hydrophobicity of the polymer/solvent system. In other words, 
factors related with core hydrophobicity, polymeric molecules self-assembly, internal pore 
distribution, and surface properties could be responsible for drug entrapment differences 
between PCL and PLGA, especially if the same operating conditions (flow rate, CIJM 
geometry) and formulation parameters (solvent type, polymer concentration, drug 
concentration) were used. In the same way, different polymer-drug interactions may play an 
important role with regards to drug loading: Barichello et al. [43] discussed about this 
phenomenon by analyzing the incorporation of hydrophilic and lipophilic drugs into PLGA 
particles by nanoprecipitation. If the solubility  of florfenicol in water is considered (the drug 
is slightly soluble), the above mentioned more hydrophobic nature of PCL would be 
associated with a lower entrapment than PLGA due to the lower affinity of hydrophilic drugs 
for hydrophobic polymers. 
Florfenicol-PCL particles had zeta potential absolute values lower than 30 mV and were still 
considered with a limited stability (Table 2). Nanoparticles obtained using 6 mg/mL of PLGA 
at different concentrations of florfenicol were stable (Table 3). Moreover, the lack of 
differences between zeta potential with and without adding florfenicol into formulation could 
suggest the absence of adsorbed antibiotic on the surface of nanoparticles. In other words, 
data suggest that all the nanoparticle-associated drug is inside polymeric matrix.  
Besides the fact that drug loading between 10 and 13% w/w for PCL and PLGA matrices, 
respectively, were obtained, encapsulation efficiencies were low (around 15%), leaving high 
wasted quantities of antibiotic out of nanoparticles when such a high quantity of drug was 
added during nanoparticle preparation. Since nanoprecipitation is most suited for hydrophobic 
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drugs, the poor efficiencies could be also related with the considerable solubility of florfenicol 
in water at room temperature (around 1000 ppm [19]). This promotes more drug partition in 
water-solvent mixture during nanoparticles preparation due to relatively high residual 
solubility in the mixture [40, 44]. Despite this, Alshamsan [36] compared nanoprecipitation 
against solvent evaporation method for the encapsulation of a polar molecule and found that 
the first reached a drug loading 12 times higher. Polymer concentrations could be increased in 
order to favor encapsulation but at risk of size distribution increase, as discussed above.  
Moreover, in literature Misra et al. [36] emphasizes the use of polymeric blends (PLGA:PCL) 
to favor entrapment of hydrophilic drugs by solvent evaporation technique. Bilati et al. [5] 
proposes the use of alcohols as non-solvents to prevent drug partition into aqueous medium 
and Govender et al. [4] analyzed other formulation approaches for improving hydrophilic 
drug encapsulation efficiencies by nanoprecipitation. 
 
4. Conclusions 
CIJM devices resulted especially attractive for nanoparticles production in a reproducible 
way. In this work in particular we have compared PCL and PLGA matrices as regards their 
ability to produce nanoparticles and entrap florfenicol. Differences in mean size, PDI and zeta 
potential could be found between nanoparticle formulations obtained from different polymer 
types, polymer concentrations, and flow rates; this resulted in smaller and more stable 
nanoparticles suspensions for PLGA than PCL. After florfenicol incorporation at four 
concentrations, PCL and PLGA nanoparticles did not change their mean size or surface zeta 
potential. Entrapment was increased for higher initial concentrations of drug. PLGA matrix 
was more able to entrap this slightly hydrophilic antibiotic with respect to PCL due to its less 
hydrophobic nature.  
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Table 1 Summary of preparation conditions and evaluated characteristics of nanoparticles 
Operating parameter Unloaded nanoparticles 
Loaded 
nanoparticles 1 
Loaded 
nanoparticles 2 
Polymer type PCL; PLGA PCL; PLGA PCL; PLGA 
Solvent Acetone Acetone Acetone 
Anti-solvent Water Water Water 
Initial polymer concentration  
(mg/mL in acetone) 2.5; 6; 10 6 6 
Flow rate (mL/min) 40; 80; 120 40; 80; 120 80 
Anti-solvent-to-solvent flow 
rate ratio 1 1 1 
Drug - Florfenicol Florfenicol 
Initial drug concentration  
(mg/mL in acetone) - 0.5; 1; 2; 5 0.5; 1; 2; 5 
Evaluated characteristics 
Mean particle size, 
particle size 
distribution, surface 
zeta potential 
Mean particle size, 
particle size 
distribution, surface 
zeta potential 
Entrapment and 
encapsulation 
efficiency of drug 
by nanoparticles 
 
 
Table 2 Mean particle size and zeta potential of nanoparticles obtained with 6 mg/mL of PCL under 
different flow rates (FR) and initial florfenicol concentrations 
 Florfenicol initial concentration (mg/mL in acetone) 
 0 0.5 1 2 5 
FR (mL/min) Size distribution (mean (SD), n = 3), nm 
40 280.0 (14.0)*,** 293.8 (4.9)* 282.7 (7.5)*,** 269.7 (9.0)** 284.8 (7.5)*,** 
80 270.9 (24.6)* 286.5 (12.6)* 278.6 (3.0)* 264.3 (21.3)* 265.9 (9.9)* 
120 265.8 (6.6)* 275.9 (5.4)* 263.7 (2.8)* 240.3 (15.3)* 275.0 (6.3)* 
FR (mL/min) Zeta potential (mean (SD), n = 3), mV 
40 -22.1 (0.5) -21.2 (4.0) -23.3 (0.9) -20.7 (1.0) -19.1 (2.2) 
80 -22.1 (1.1) -21.1 (0.9) -26.3 (3.5) -20.2 (2.0) -18.5 (4.4) 
120 -20.6 (1.2) -20.9 (0.8) -23.3 (1.3) -20.1 (1.5) -18.2 (2.3) 
*,** Means statistically equals between columns (p > 0.05). 
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Table 3 Mean particle size and zeta potential of nanoparticles obtained with 6 mg/mL of 
PLGA under different flow rates (FR) and initial florfenicol concentrations 
 Florfenicol initial concentration (mg/mL in acetone) 
 0 0.5 1 2 5 
FR (mL/min) Size distribution (mean (SD), n = 3), nm 
40 101.8 (3.0)* 100.7 (4.6)* 93.6 (6.0)*,** 91.2 (4.8)** 101.9 (3.9)* 
80 93.5  (4.7)* 95.4 (6.0)* 95.4 (11.4)* 97.4 (16.6)* 95.4 (2.9)* 
120 81.7 (0.6)* 78.1 (4.2)* 80.0 (5.2)* 80.5 (9.2)* 78.1 (5.2)* 
FR (mL/min) Zeta potential (mean (SD), n = 3), mV 
40 -37.3 (1.4) -41.4 (5.2) -31.7 (2.5) -37.5 (2.5) -37.6 (3.2) 
80 -38.1 (1.6) -32.4 (6.4) -30.8 (3.8) -35.4 (3.7) -36.1 (10.0) 
120 -34.4 (3.1) -37.5 (4.2) -36.8 (1.5) -37.0 (3.0) -38.8 (5.2) 
*,** Means statistically equals between columns (p > 0.05). 
 
 
  
 
Table 4 Mean (and standard deviation) florfenicol entrapment (En, % w/w) of loaded 
nanoparticles based on 6 mg/mL of polymer and flow rate of 80 mL/min 
 Florfenicol initial concentration (mg/mL in acetone) 
Polymer 0.5  1 2 5 
PCL 0  0 1.54 (0.14) 10.12 (0.37) 
PLGA 0.76 (0.10) 2.21 (0.19) 5.39 (0.27) 12.93 (0.48) 
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Figure captions: 
Fig. 1 Chemical structures of considered polymers and drug 
Fig. 2 Scheme of the confined impinging jet mixer used. Dc=4.8 mm, din=1 mm, dout=2 mm; 
H is aproximately equal to 2Dc 
Fig. 3 Mean size of PCL (filled symbols) and PLGA (empty symbols) nanoparticles obtained 
under different flow rates (A) for (■,□) 2.5, (●,○) 6 and (▲,Δ) 10 mg/mL of polymer, and 
under different polymer concetrations (B) at flow rate 80 mL/min. The trend lines were 
calculated using Eq. (3), with α=0.29 and β=–0.18; error bars in Fig. 3B are smaller than 
symbols. 
Fig. 4 Relative mean size increment (A) under different flow rates for (●,○) 6 and (▲,Δ) 10 
mg/mL of polymer, and polydispersity index of size distribution (B) under different polymer 
concentrations (flow rate 80 mL/min) for nanoparticles obtained with PCL (filled symbols) 
and PLGA (empty symbols).  
Fig. 5 (a) Zeta potential of nanoparticles obtained with different concentrations of PCL (filled 
symbols) and PLGA (empty symbols)  at  flow rates of  (▲,Δ) 40, (●,○) 80 and 
(■,□) 120 mL/min. (b)  Relationship between the mean particle size and zeta potential of 
nanoparticles based on (■) PCL and (□) PLGA. 
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